Home
Zydus Lifesciences Ltd PE Ratio

Zydus Lifesciences Ltd
NSE: ZYDUSLIFE
PE
Key Highlights
- The P/E Ratio of Zydus Lifesciences Ltd is 20.3 as of 19 Feb 14:34 PM .
- The P/E Ratio of Zydus Lifesciences Ltd changed from 23.3 on March 2020 to 26.2 on March 2024 . This represents a CAGR of 2.37% over 5 years.
- The Latest Trading Price of Zydus Lifesciences Ltd is ₹ 888.75 as of 19 Feb 14:24 .
- The PE Ratio of Pharmaceuticals Industry has changed from 21.0 to 40.0 in 5 years. This represents a CAGR of 13.75%.
- The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 36.9 in 2024.
Historical P/E Ratio of Zydus Lifesciences Ltd
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Historical P/E Ratio of Zydus Lifesciences Ltd
Company Fundamentals for Zydus Lifesciences Ltd

Zydus Lifesciences Ltd
NSE: ZYDUSLIFE
Share Price
Market Price of Zydus Lifesciences Ltd
1M
1Y
3Y
5Y
Last Ten Days Market Price
Date | |
---|---|
18 Feb 2025 | 913.2 |
17 Feb 2025 | 924.15 |
14 Feb 2025 | 901.6 |
13 Feb 2025 | 942.45 |
12 Feb 2025 | 934.2 |
11 Feb 2025 | 941.65 |
10 Feb 2025 | 964.45 |
07 Feb 2025 | 993.95 |
06 Feb 2025 | 1008.3 |
05 Feb 2025 | 978.25 |
SWOT Analysis Of Zydus Lifesciences Ltd
BlinkX Score for Zydus Lifesciences Ltd
Asset Value vs Market Value of Zydus Lifesciences Ltd
Market Value
₹ 0
Asset Value
₹ 0
* All values are in ₹ crores
Competitive Comparison of P/E Ratio
Company | Market Cap | PE Ratio |
---|
Zydus Lifesciences Ltd | 91889 | 20.27 |
Sun Pharmaceuticals Industries Ltd | 408259 | 34.6 |
Divis Laboratories Ltd | 154917 | 74.9 |
Cipla Ltd | 119705 | 24.0 |
Torrent Pharmaceuticals Ltd | 103096 | 55.4 |
Dr Reddys Laboratories Ltd | 99951 | 18.6 |
Company | |
---|---|
Zydus Lifesciences Ltd | 91889 |
Sun Pharmaceuticals Industries Ltd | 408259 |
Divis Laboratories Ltd | 154917 |
Cipla Ltd | 119705 |
Torrent Pharmaceuticals Ltd | 103096 |
Dr Reddys Laboratories Ltd | 99951 |
PE Ratio of Zydus Lifesciences Ltd Explained
₹91889
Market cap
₹4536
Earnings
20.3X
PE Ratio
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.
P/E Ratio Formula
P/E ratio = (CMP of share/ Earning per share)
Types of Price to Earning Ratio
1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
PE Ratio of Pharmaceuticals Industry over time
PE Ratio of Top Sectors
Historical Market Cap of Zydus Lifesciences Ltd
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Historical Market Cap of Zydus Lifesciences Ltd
Historical Revenue, EBITDA and Net Profit of Zydus Lifesciences Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Historical Revenue, EBITDA and Net Profit of Zydus Lifesciences Ltd
Revenue
EBITDA
Net Profit
Historical Dividend Payout of Zydus Lifesciences Ltd
Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.
Historical Dividend Payout of Zydus Lifesciences Ltd
About Zydus Lifesciences Ltd
- Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products.
- The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh. Founded by the Late Promoter, Mr. Ramanbhai B. Patel, the Company was incorporated in May, 1995 and converted into a Public Limited Company in July, 1996.
Zydus Lifesciences Ltd News Hub
Zydus Life gains as Q1 PAT climbs 31% YoY to Rs 1,420 cr
Revenue from operations jumped 20.77% year on year (YoY) to Rs 6,207.5 crore in the quareter ended 3
Read more
09 Aug 24
Zydus Lifesciences consolidated net profit rises 30.64% in the June 2024 quarter
Net profit of Zydus Lifesciences rose 30.64% to Rs 1419.90 crore in the quarter ended June 2024 as a
Read more
09 Aug 24
Zydus receives USFDA approval for Valbenazine Capsules
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (
Read more
09 Aug 24
Zydus Lifesciences Ltd soars 1.83%, rises for third straight session
Zydus Lifesciences Ltd is up for a third straight session in a row. The stock is quoting at Rs 1296.
Read more
08 Aug 24